Search Results
Mar 17, 2026, 09:00 ET Metabolon Collaborates with The Michael J. Fox Foundation to Advance Multiomic Analyses for Parkinson's Research
leaders, and provide preclinical and clinical resources to establish best practices for advancing LRRK2-targeted therapeutics. Mutations in the LRRK2 gene linked to Parkinson's disease were first discovered in 2004 and are now understood to be the most common cause of inherited Parkinson's disease. Built
More news about: Metabolon, Inc.
Mar 17, 2026, 08:00 ET PerturbAI Launches from Stealth, Unveils the World's Largest In Vivo CRISPR Atlas
generated and analyzed in collaboration with NVIDIA, Allen Institute for Brain Science and 10x Genomics, establishes the largest causal map of gene function in living tissue, showcasing the power of PerturbAI's scalable discovery engine -SAN
More news about: PerturbAI
Mar 17, 2026, 08:00 ET Intellitech and Cole-Parmer Unite to Bring Next‑Generation Micro Filling Technology to Global Markets
environments where sterility, dose accuracy, and workflow reliability are non‑negotiable, the i‑FILL Micro supports applications in bioprocessing, cell and gene therapy, R&D, process development, QA/QC, formulation, and small‑batch aseptic fill/finish. Its single‑use fluid path, hybrid piston/diaphragm design,
More news about: Cole-Parmer
Mar 17, 2026, 06:38 ET MGI Tech and Predica Diagnostics Accelerate Cervical Cancer Screening on DNBSEQ Platforms
national cervical cancer screening programs. The integrated solution offers:Simultaneous high-resolution HPV genotyping and host-gene expression profilingImproved specificity for cervical cancer risk assessment and HPV+ triageAutomated analysis and reporting through
More news about: MGI Tech Co., Ltd.
Mar 17, 2026, 03:46 ET GLP-1 Receptor Agonist Market to Hit USD 78.4 Billion by 2032, Growing at a CAGR of 3.66% with Rising Demand for Metabolic Disease Therapies | MarkNtel Advisors
Global Cell & Gene Therapy Drug Delivery Devices Market: The Global Cell & Gene Therapy Drug Delivery Devices Market size was valued at around USD 1.27 billion in 2024 and is projected to reach
More news about: MarkNtel Advisors
Mar 16, 2026, 15:05 ET QURE INVESTOR ALERT: uniQure Faces Securities Class Action Over AMT-130 Clinical Trial Design - Hagens Berman
The lawsuit alleges that the defendants made inaccurate and misleading statements regarding the regulatory path for its lead gene therapy candidate, AMT-130, specifically concerning the FDA's acceptance of a "pivotal" study design that omitted a traditional placebo control.Hagens
More news about: Hagens Berman Sobol Shapiro LLP
Mar 16, 2026, 13:00 ET ApoE4.Info and ApoE4 Alzheimer's Alliance Announce Partnership to Advance Precision Advocacy for ApoE4 Carriers
announced a strategic partnership to elevate research, education, and public policy efforts focused on individuals who carry the ε4 allele of the APOE gene (APOE4)—the strongest genetic risk factor for late-onset Alzheimer's disease. APOE4 carriers represent up to 65% of people diagnosed with
More news about: ApoE4.Info and ApoE4 Alzheimer's Alliance
Mar 16, 2026, 08:01 ET Sentynl Therapeutics Enters into Agreement with PRG S&T to License Molecule for Hutchinson-Gilford Progeria Syndrome
in children. The disease is caused by the accumulation of progerin, an abnormal form of the lamin A protein produced by mutations in the LMNA gene, which disrupts nuclear structure and leads to premature cellular aging. Progerinin is designed to inhibit the interaction and harmful effects of progerin
More news about: Sentynl Therapeutics
Mar 16, 2026, 08:00 ET Argo Biopharma Receives FDA Fast Track Designation for BW-20805, an Investigational siRNA Therapy for the Treatment of HAE
are limited by frequent dosing, highlighting the need for long-acting, preventive therapies. BW-20805 targets human hepatic PKK mRNA to inhibit PKK gene expression, offering the potential for effective prevention of HAE attacks with a significant and longer-lasting therapeutic effect.About
More news about: Argo Biopharmaceutical Co., Ltd
Mar 16, 2026, 07:00 ET Prestige Consumer Healthcare Selects Horizon Media as Agency of Record to Drive Market Growth
consumer engagement and business results.""Consumers expect brands to meet them where they are, with relevance, empathy, and authenticity," said Gene Turner, President Chief Global Client Officer at Horizon Media. "Through a unified measurement framework, we'll enable smarter investments, clearer
More news about: Horizon Media
Mar 16, 2026, 06:26 ET GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
of its integrated gene-to-protein platform, strong demand from pharma and biotech customers, and growing traction in AI-enabled discovery.Among key highlights:Revenue from integrated protein expression services grew +50%.Orders flowing from gene synthesis into integrated
More news about: GenScript Biotech Corporation
Mar 16, 2026, 06:10 ET GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
of its integrated gene-to-protein platform, strong demand from pharma and biotech customers, and growing traction in AI-enabled discovery.Among key highlights:Revenue from integrated protein expression services grew +50%.Orders flowing from gene synthesis into integrated
More news about: GenScript Biotech Corporation
Mar 16, 2026, 05:31 ET Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited.For more information visit:
More news about: Piramal Pharma Solutions
Mar 16, 2026, 05:27 ET Piramal Pharma Solutions' Grangemouth, UK Facility Successfully Delivers 1,500th ADC Batch
products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited's associate company, Yapan Bio Private Limited.For more information visit:
More news about: Piramal Pharma Solutions
Mar 16, 2026, 02:00 ET Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease
Elecsys® Apolipoprotein E4 biomarker test – the first in-vitro diagnostic (IVD) immunoassay to identify the presence of the ApoE4 gene variant in the bloodstream. The ApoE4 gene variant is associated with an increased risk of late-onset Alzheimer's disease, and is present in approximately 40–60% of Alzheimer's
More news about: Roche
Mar 16, 2026, 02:00 ET Roche receives CE mark for first IVD immunoassay blood test to identify carriers of ApoE4, a genetic variant present in up to 60% of patients diagnosed with Alzheimer's disease
Elecsys® Apolipoprotein E4 biomarker test – the first in-vitro diagnostic (IVD) immunoassay to identify the presence of the ApoE4 gene variant in the bloodstream. The ApoE4 gene variant is associated with an increased risk of late-onset Alzheimer's disease, and is present in approximately 40–60% of Alzheimer's
More news about: Roche
Mar 13, 2026, 17:55 ET RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: THE ROSEN LAW FIRM, P. A.
Mar 13, 2026, 14:34 ET uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline
COMPLAINT ALLEGATION SUMMARY:uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate is AMT-130, a novel gene therapy being developed to slow the progression of HD. During the Class Period, uniQure
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 13, 2026, 08:06 ET Unixell Biotech receives IND clearance by FDA for its Allogeneic iPSC-Derived cell therapy, UX-GIP001, for focal Epilepsy
technology platforms based on reprogramming technology, stem cell differentiation technology, SISBAR lineage tracing technology, and high-precision gene editing. These platforms facilitate the development and production of neural cell drugs with higher purity and more stable efficacy, ensuring efficient
More news about: Unixell Biotech
Mar 12, 2026, 18:53 ET Lockheed Martin Skunk Works' DARKSTAR Revisited: The Untold Secrets! at The Palm Springs Air Museum
available at the door. The viewing, lecture and reception takes place inside the General Miles Hangar at the Palm Springs Air Museum, located at 745 N. Gene Autry Trail, Palm Springs, CA 92262. Click
More news about: Palm Springs Air Museum
Mar 12, 2026, 16:05 ET INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Forum in November 2025. This technology aims to address some of the shortcomings of conventional therapeutic protein replacement treatments, including gene therapy approaches. INOVIO is developing additional DPROT indications and is actively seeking partners to accelerate development of this promising program.General
More news about: INOVIO Pharmaceuticals, Inc.
Mar 12, 2026, 15:24 ET QURE ALERT: FDA Reportedly Accuses uniQure of Pushing "Distorted" and "Manipulated" Data For "Failed" AMT-130 Drug Amid Pending Securities Class Action - Hagens Berman
said in a call with reporters Thursday that the data from the testing of Uniqure's gene therapy were flawed and signaled the drug candidate didn't meet the bar for agency approval." The therapy at issue is uniQure's lead gene therapy candidate, AMT-130, which is being developed to slow the progression of
More news about: Hagens Berman Sobol Shapiro LLP
Mar 12, 2026, 12:11 ET Carsten Bönnemann, MD, joins St. Jude to expand research on pediatric catastrophic neurological disorders
amyotrophic lateral sclerosis, advancing understanding of the genetics of neuromuscular disorders and the first in-human intrathecal application of AAV gene therapy for giant axonal neuropathy."Joining St. Jude is an extraordinary opportunity to accelerate discoveries for children with catastrophic
More news about: St. Jude Children's Research Hospital
Mar 12, 2026, 11:00 ET Lurie Autism Institute Announces Dr. Huda Zoghbi as the Inaugural Recipient of the Nancy Lurie Marks Prize for Autism Research
disease – including autism spectrum disorder – by integrating human genetics, animal models, and systems-level neuroscience to define how disruptions in gene regulation, neuronal maturation, and circuit function drive disease."When thinking of an appropriate inaugural recipient of the Nancy Lurie Marks
More news about: Children's Hospital of Philadelphia
Mar 12, 2026, 10:31 ET Stämm Redefines Biomanufacturing With a Bubble-Free, High-Throughput Bioprocessor Built for Decentralized Production
infrastructure constraints that slow research and development, and future versions aim to accelerate the development process of biologics and cell & gene therapies. Easy to use and designed for deployment anywhere in the world, the HTB targets the widening gap between biological discovery and the scalable
More news about: Stämm